STANOHA

Serial Number 97036217
606

Registration Progress

Application Filed
Sep 20, 2021
Under Examination
Aug 30, 2022
Approved for Publication
Jul 5, 2022
Published for Opposition
Jul 5, 2022
Registered

Basic Information

Serial Number
97036217
Filing Date
September 20, 2021
Published for Opposition
July 5, 2022
Abandonment Date
April 3, 2023
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 3, 2023
Classes
005

Rights Holder

Aprecia Pharmaceuticals, LLC

16
Address
10901 Kenwood Rd
Blue Ash, OH 45242

Ownership History

Aprecia Pharmaceuticals, LLC

Original Applicant
16
Blue Ash, OH

Aprecia Pharmaceuticals, LLC

Owner at Publication
16
Blue Ash, OH

Legal Representation

Attorney
Carole R. Klein

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

18 events
Date Code Type Description
Apr 3, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Apr 3, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Aug 30, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 5, 2022 PUBO A PUBLISHED FOR OPPOSITION
Jul 5, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 15, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 28, 2022 ALIE A ASSIGNED TO LIE
May 26, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN
May 26, 2022 GNEA F EXAMINERS AMENDMENT E-MAILED
May 26, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 26, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED
May 26, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
May 23, 2022 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN
May 17, 2022 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY
May 3, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 27, 2022 DOCK D ASSIGNED TO EXAMINER
Oct 24, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 23, 2021 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of neurogenic orthostatic hypotension and for the prevention and treatment of low blood pressure; pharmaceutical preparations for the prevention and treatment of Parkinson's disease and disorder; pharmaceutical preparations for the prevention and treatment of dizziness and lightheadedness
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005